TNFRSF17 and plasma cell myeloma: CAR-modified T cells (CAR-T) targeting CD19 have induced impressive responses in chemotherapy-resistant B cell leukemias and lymphomas [5, 6], while B cell maturation antigen (BCMA)–targeting CAR-T cells show promising clinical results against multiple myeloma [7].